Atox Bio, Fast-Track Drugs & Biologics Sign Collaboration Agreement

Atox Bio and Fast-Track Drugs & Biologics have signed R&D collaboration agreement for the development of Atox Bio’s novel mechanism-based immunomodulator peptide, AB103. It is intended for the treatment of sepsis and septic shock.

AB103 is an immunomodulator that attenuates the excessive Th1 cytokine responses caused by the majority of sepsis virulence factors, Gram-positive bacteria, Gram-negative bacteria, and superantigen toxins.

The collaboration includes advanced pre-clinical studies and a phase-I clinical trial to be performed at the University of Maryland. The collaborative R&D program has been funded by the Israel-US Binational Industrial Research and Development Fund (BIRD), for the amount of $575,000.

Uri Danon, CEO of Atox Bio, said: This collaboration combines Atox Bio’s break-through technology, the proven regulatory and clinical management capabilities of Fast-Track and the University of Maryland School of Medicine’s strong clinical capabilities. This combined expertise will contribute to the success of the collaborative R&D program.